These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1103 related items for PubMed ID: 17031284

  • 41. An optical coherence tomography-guided, variable dosing regimen with intravitreal ranibizumab (Lucentis) for neovascular age-related macular degeneration.
    Fung AE, Lalwani GA, Rosenfeld PJ, Dubovy SR, Michels S, Feuer WJ, Puliafito CA, Davis JL, Flynn HW, Esquiabro M.
    Am J Ophthalmol; 2007 Apr; 143(4):566-83. PubMed ID: 17386270
    [Abstract] [Full Text] [Related]

  • 42. A phase I trial of an IV-administered vascular endothelial growth factor trap for treatment in patients with choroidal neovascularization due to age-related macular degeneration.
    Nguyen QD, Shah SM, Hafiz G, Quinlan E, Sung J, Chu K, Cedarbaum JM, Campochiaro PA, CLEAR-AMD 1 Study Group.
    Ophthalmology; 2006 Sep; 113(9):1522.e1-1522.e14. PubMed ID: 16876249
    [Abstract] [Full Text] [Related]

  • 43. In vivo three-dimensional imaging of neovascular age-related macular degeneration using optical frequency domain imaging at 1050 nm.
    de Bruin DM, Burnes DL, Loewenstein J, Chen Y, Chang S, Chen TC, Esmaili DD, de Boer JF.
    Invest Ophthalmol Vis Sci; 2008 Oct; 49(10):4545-52. PubMed ID: 18390638
    [Abstract] [Full Text] [Related]

  • 44. A 1-year retrospective review of ranibizumab for naive nonsubfoveal choroidal neovascularization secondary to age-related macular degeneration.
    Arias L, Ruiz-Moreno JM, Gómez-Ulla F, Fernández M, Montero J.
    Retina; 2009 Oct; 29(10):1444-9. PubMed ID: 19730163
    [Abstract] [Full Text] [Related]

  • 45. Antivascular endothelial growth factors in age-related macular degeneration.
    Schmidt-Erfurth U, Pollreisz A, Mitsch C, Bolz M.
    Dev Ophthalmol; 2010 Oct; 46():21-38. PubMed ID: 20703030
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Antivascular endothelial growth factor therapy for neovascular age-related macular degeneration.
    Ciulla TA, Rosenfeld PJ.
    Curr Opin Ophthalmol; 2009 May; 20(3):158-65. PubMed ID: 19417570
    [Abstract] [Full Text] [Related]

  • 48. [Antivasoproliferative agents in ophthalmology].
    Ambresin A, Zografos L, Mantel I.
    Rev Med Suisse; 2010 Jan 13; 6(231):51-4. PubMed ID: 20196434
    [Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD).
    Rasmussen H, Chu KW, Campochiaro P, Gehlbach PL, Haller JA, Handa JT, Nguyen QD, Sung JU.
    Hum Gene Ther; 2001 Nov 01; 12(16):2029-32. PubMed ID: 11727737
    [Abstract] [Full Text] [Related]

  • 51. [Monoclonal antibodies targeting VEGF in ophthalmology: the case of exudative age-related macular degeneration].
    Leveziel N, Soubrane G, Souied EH.
    Med Sci (Paris); 2009 Dec 01; 25(12):1105-7. PubMed ID: 20035686
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Aflibercept for age-related macular degeneration: a game-changer or quiet addition?
    Browning DJ, Kaiser PK, Rosenfeld PJ, Stewart MW.
    Am J Ophthalmol; 2012 Aug 01; 154(2):222-6. PubMed ID: 22813448
    [Abstract] [Full Text] [Related]

  • 54. Ranibizumab for age-related macular degeneration: a meta-analysis of dose effects and comparison with no anti-VEGF treatment and bevacizumab.
    Jiang S, Park C, Barner JC.
    J Clin Pharm Ther; 2014 Jun 01; 39(3):234-9. PubMed ID: 24635444
    [Abstract] [Full Text] [Related]

  • 55. Current therapeutic approaches in neovascular age-related macular degeneration.
    Nguyen DH, Luo J, Zhang K, Zhang M.
    Discov Med; 2013 Jun 01; 15(85):343-8. PubMed ID: 23819948
    [Abstract] [Full Text] [Related]

  • 56.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 57. Profile of conbercept in the treatment of neovascular age-related macular degeneration.
    Lu X, Sun X.
    Drug Des Devel Ther; 2015 Jun 01; 9():2311-20. PubMed ID: 25960634
    [Abstract] [Full Text] [Related]

  • 58. Review of combination therapies for neovascular age-related macular degeneration.
    Couch SM, Bakri SJ.
    Semin Ophthalmol; 2011 May 01; 26(3):114-20. PubMed ID: 21609223
    [Abstract] [Full Text] [Related]

  • 59. [Guidance for the treatment of neovascular age-related macular degeneration (AMD)].
    Karska-Basta I, Kubicka-Trzaska A, Oleksy P, Romanowska-Dixon B.
    Przegl Lek; 2009 May 01; 66(11):972-5. PubMed ID: 20297641
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 56.